NCT01503216

Brief Summary

The aim of this study is to investigate the bioavailability of vitamin D2 and D3 as measured by the increase of the specific hydroxy forms in serum (25(OH)D2 and 25(OH)D3, respectively, and by total 25(OH)D.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2012

Shorter than P25 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 24, 2011

Completed
2 months until next milestone

Study Start

First participant enrolled

January 1, 2012

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 2, 2012

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2012

Completed
Last Updated

October 10, 2012

Status Verified

October 1, 2012

Enrollment Period

4 months

First QC Date

October 24, 2011

Last Update Submit

October 7, 2012

Conditions

Keywords

randomized controlled trialvitamin Dbioavailability

Outcome Measures

Primary Outcomes (1)

  • change of 25-hydroxvitamin D

    after 4 and 8 weeks of supplementation

Study Arms (3)

cholecalciferol

EXPERIMENTAL

Human volunteers receiving cholecalciferol (vitamin D3) for 8 weeks

Dietary Supplement: cholecalciferol

Ergocalciferol

EXPERIMENTAL

Ergocalciferol 2000 IU per day for 8 weeks

Dietary Supplement: ergocalciferol

Placebo

PLACEBO COMPARATOR

Placebo for 8 weeks

Dietary Supplement: Placebo

Interventions

cholecalciferolDIETARY_SUPPLEMENT

cholecalciferol, 2000 IU per day, 8 weeks

Also known as: Cholecalciferol, vitamin D3
cholecalciferol
ergocalciferolDIETARY_SUPPLEMENT

vitamin d2, 2000 IU per day for 8 weeks

Ergocalciferol
PlaceboDIETARY_SUPPLEMENT

Placebo

Placebo

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years
  • healthy

You may not qualify if:

  • supplementation of vitamin d and calcium
  • hypercalcemia
  • hypercalciuria
  • chronical illness (diabetes, kidney diseases, cardiovascular diseases)
  • serum-creatinine above 115 mmol/l
  • pregnancy or breastfeeding women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Lehmann U, Hirche F, Stangl GI, Hinz K, Westphal S, Dierkes J. Bioavailability of vitamin D(2) and D(3) in healthy volunteers, a randomized placebo-controlled trial. J Clin Endocrinol Metab. 2013 Nov;98(11):4339-45. doi: 10.1210/jc.2012-4287. Epub 2013 Sep 3.

MeSH Terms

Conditions

Vitamin D Deficiency

Interventions

CholecalciferolErgocalciferols

Condition Hierarchy (Ancestors)

AvitaminosisDeficiency DiseasesMalnutritionNutrition DisordersNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

CholestenesCholestanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSterolsVitamin DSecosteroidsMembrane LipidsLipids

Study Officials

  • Jutta Dierkes, Prof. Dr.

    Institut für Agrar- und Ernährungswissenschaften

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

October 24, 2011

First Posted

January 2, 2012

Study Start

January 1, 2012

Primary Completion

May 1, 2012

Study Completion

May 1, 2012

Last Updated

October 10, 2012

Record last verified: 2012-10